Preview Mode Links will not work in preview mode

Feb 11, 2025

Featuring perspectives from Dr Enriqueta Felip and Dr Helena Yu, including the following topics:

  • Introduction (0:00)
  • First-Line Treatment of Metastatic Disease (2:34)
  • Adjuvant and Neoadjuvant Therapy (22:31)
  • EGFR Exon 20 Insertion Mutations (34:21)
  • Antibody-Drug Conjugates (42:45)

CME information and select...


Feb 9, 2025

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 2: Other Relevant Topics in EGFR Mutation-Positive NSCLC, Such as Nonmetastatic Disease, Exon 20 Insertion Mutations and Novel Agents — Helena Yu, MD


Feb 8, 2025

Featuring an interview with Dr Seth Wander, including the following topics:

  • Therapy selection after CDK4/6 inhibitor failure: A review of current and investigational treatment for HR-positive, HER2-negative breast cancer
    • Astore S et al. A therapeutic algorithm guiding subsequent therapy selection after CDK4/6...


Feb 7, 2025

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 1: Management of Metastatic EGFR Mutation-Positive NSCLC — Enriqueta Felip, MD, PhD

CME information and select...


Feb 6, 2025

Featuring an interview with Dr Saad Zafar Usmani, including the following topics:

  • Optimizing treatment intervention for patients with newly diagnosed multiple myeloma (MM) (0:00)
  • Role of anti-CD38 antibodies in induction and maintenance therapy for patients with newly diagnosed disease (4:22)
  • Case: A woman in her late...